MedTrace Logo

Making Football Safer for Women: Implementing an Injury Prevention Program

NCT04856241 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2600

Last updated 2023-10-11

No results posted yet for this study

Summary

The aim of this study is to determine how we can best support coaches to implement an injury prevention (IP) program (Prep-to-Play) in female community Australian Football. We will recruit at least 140 female community football teams from 15 different football leagues in Victoria, Australia. Teams will be competing in U16, U17, U18, U19 or open womens competitions. We will train and support coaches to implement the IP program and evaluate the effects of the IP program on injuries across two football seasons.

Conditions

  • Anterior Cruciate Ligament Injuries
  • Concussion, Brain
  • Musculoskeletal Injury

Interventions

OTHER

Coaching

Physiotherapists (trained by the research team) train the coaches to deliver Prep-to-Play. The Physiotherapists will also provide face-to-face one-to-one support to each coach at their team's training session (two visits), with all their players.

OTHER

Peer support

Coaches shed. Coaches provide each other with support and ideas. Strategies to overcome barriers and motivate players.

OTHER

Educational materials

Prep-to-Play program resources are available online for coaches and players to view

Sponsors & Collaborators

  • La Trobe University

    lead OTHER

Principal Investigators

  • Kay Crossley, PhD, PT · La Trobe University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
14 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-22
Primary Completion
2025-04-13
Completion
2025-12-21

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04856241 on ClinicalTrials.gov